The DOI matches its Crossref record, with a small difference in title or year; 53 of the 53 references it cites were found in a registry or an index.
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Open accessAbstract
Objectives Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function.Background NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density lipoprotein cholesterol and is widely used as an adjunct to statin therapy in patients with coronary artery disease. Although changes in plasma lipoproteins suggest potential benefit, there is limited evidence of the effects of NA on disease progression when added to contemporary statin treatment.Methods We performed a double-blind, randomized, placebo-controlled study of 2 g daily modified-release NA added to statin therapy in 71 patients with low HDL-C (<40 mg/dl) and either: 1) type 2 diabetes with coronary heart disease; or 2) carotid/peripheral atherosclerosis. The primary end point was the change in carotid artery wall area, quantified by magnetic resonance imaging, after 1 year.Results NA increased HDL-C by 23% and decreased low-density lipoprotein cholesterol by 19%. At 12 months, NA significantly reduced carotid wall area compared with placebo (adjusted treatment difference: -1.64 mm(2) [95% confidence interval: -3.12 to -0.16]; p = 0.03). Mean change in carotid wall area was -1.1 +/- 2.6 mm(2) for NA versus +1.2 +/- 3.0 mm(2) for placebo. In both the treatment and placebo groups, larger plaques were more prone to changes in size (r = 0.4, p = 0.04 for placebo, and r = -0.5, p = 0.02 for NA).Conclusions In statin-treated patients with low HDL-C, high-dose modified-release NA, compared with placebo, significantly reduces carotid atherosclerosis within 12 months. (Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function; NCT00232531).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In statin-treated patients with low HDL-C, high dose, modified release nicotinic acid, compared with placebo, significantly reduced carotid wall area, quantified by magnetic resonance imaging after 1 year.133”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [133]
In the citing paper
“A recent meta-analysis suggests that nicotinic acid alone or in combination with statin may add further benefit in stroke prevention.133”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–246 of 246
Modulation of Lipid Metabolism by Phytosterol Stearates and Black Raspberry Seed Oils
Ash, M. M. (2010) · Lincoln (University of Nebraska) · Cited by 1
Lipid Lowering in Coronary Artery Disease
Ray, K. K., & Cannon, C. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2358-8.00010-3 · Cited by 1
Drugs that affect lipid metabolism
Nestel, P. J. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00044-1 · Cited by 1
Yilmaz, B. A., & Törüner, F. B. (2013) · CRC Press eBooks · doi:10.1201/b14907-9 · Cited by 1
Endothelial Dysfunction in Type 2 Diabetes with an Update on New Interventions
Ward, N. C., Loh, W. J., & Watts, G. F. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_14 · Cited by 2
Guyton, J. R., McGovern, M. E., & Carlson, L. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00024-4 · Cited by 1
Nutritional Impact on the Nitric Oxide Pathway
Wong, W. T., & Cooke, J. P. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-616-0_7 · Cited by 1
Nofer, J. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c224d · Cited by 1
Lipid Regulation with Niacin Extended-Release (Niaspan-R™)
Vosper, H. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s5155 · Cited by 1
Therapy and clinical trials: nicotinic acid in the management of atherosclerotic disease
Udiawar, M., & Rees, A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283395475 · Cited by 1
Imaging coronary atherosclerosis: is there space for magnetic resonance imaging?
Andrews, J., & Nicholls, S. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.22 · Cited by 1
Highlights of the Year in JACC2009
DeMaria, A. N., Bax, J. J., Ben‐Yehuda, O., Feld, G. K., Greenberg, B., Hall, J. L., Hlatky, M. A., Lew, W. Y. W., Lima, J. A. C., Maisel, A. S., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.007 · Cited by 1
Aye, M. M. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 1
Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL
Schwarz, M., & Kim, J. B. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch8
Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling
Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678.ch11
Drugs that affect lipid metabolism
Nestel, P. J. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00044-1
Duivenvoorden, R., & Fayad, Z. A. (1996) · doi:10.1002/9780470034590.emrstm1175
Iqbal, O., Syed, D., & Fareed, J. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_220
Therapy and clinical trials: new insights
Pellegatta, F., Grigore, L., & Catapano, A. L. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c2260
Extended-release niacin and laropiprant in the management of dyslipidemias
Farnier, M. (2010) · Clinical Lipidology · doi:10.2217/clp.10.66
Lipoproteínas de alta densidad y regresión de la arteriosclerosis: desde la teoría hasta la imagen
Ibáñez, B. (2010) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(10)70016-4
Lindsay, A. C., & Choudhury, R. P. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.65
Self-citationARBITER 6-HALTS. Does it have the power to settle all matters?
Ferrario, C. M. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709359518
“Multiple studies demonstrate a beneficial effect of niacin on both LDL and HDL-cholesterol fractions and decreases in large plaque formation and in the progression of atherogenesis [Lee et al. 2009; Cziraky et al. 2008; Goldberg, 1998; McKenney et al. 1998; Keenan et al. 1991; Alderman et al. 1989; Blankenhorn et al.…”
BackgroundChoudhury, R. P. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833768ea
Self-citationCETP Pharmacological Manipulation Transforming Human into Mouse: Is this Still a Viable Hypothesis?
Morales-Villegas, E., Moreno-Virgen, G., & Barter, P. J. (2012) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152212803521057
“This article has reviewed the evidence with CETP pharmacological manipulation, other strategies such as the use of niacin [88-92], fibrates [93-95], ACAT inhibitors [96-98], HDL infusion, apoAI infusion (native, Milano, mimetics or regulators) [99103] etc.”
MethodBenefits of raising HDL-cholesterol levels
Mearns, B. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.243
Li, Z. (2011) · Leiden Repository (Leiden University)
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy
Hamilton, S. J., & Watts, G. F. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_13
Cardiovascular Health in Advanced Age
Teh, R. (2011) · ResearchSpace (University of Auckland)
atherosclerosis: Short-term Natural History of Lipid-rich Necrotic Core—A Multicenter Study with
Sun, J., Balu, N., Hippe, D. S., Xue, Y., Zhao, X., Li, F., Xu, D., Hatsukami, T. S., & Yuan, C. (2013)
[What is the future for niacin after the AIM-HIGH study?].
Cybulska, B., & Kłosiewicz−Latoszek, L. (2012) · PubMed
Islam, S. A., Danwada, R., Ganguli, M., Espaillat, R., Jarvis, M. F., & Bacher, H. P. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517745650
Advances in cardiovascular imaging
Rollins, A. M. (2019) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2019.05.001
Nutritional Impact on the Nitric Oxide Pathway
Wong, W. T., & Cooke, J. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-46189-2_9
Vascular disease: Benefits of raising HDL-cholesterol levels
Mearns, B. M. (2010) · Lipidomics Gateway · doi:10.1038/lipidmaps.2010.5
Iqbal, O., Syed, D., & Fareed, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_220-1
Capristo, E., Malandrino, N., Farnetti, S., Mingrone, G., Leggio, L., Addolorato, G., & Gasbarrini, A. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d6b9d6
Long Way of Evaluating Niacin for Atherosclerosis Treatment
Poznyak, A. V., Khotina, V. A., Pleshko, E. M., Sukhorukov, V. N., Glanz, V. Y., & Orekhov, A. N. (2024) · OnLine Journal of Biological Sciences · doi:10.3844/ojbsci.2024.349.357
“The trial reported a decrease in CIMT over a 1 year follow up period (Lee et al ., 2009).”
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26094488
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26738268
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26738271
Sohouli, M. H., Tavakoli, S., Reis, M. G., Hekmatdoost, A., & Guimarães, N. S. (2024) · Figshare · doi:10.6084/m9.figshare.26094402
Non-statin Therapies for CKD with Dyslipidemia
Mucsi, I. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_9
Atherosclerosis Imaging Using Cardiovascular Magnetic Resonance
Woods, K. M., & Weissman, G. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4288-1_11
Metadata
- Authors
- Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., Durrington, P. N., Channon, K. M., Neubauer, S., & Choudhury, R. P.
- Affiliations
- University of Oxford (GB)
- University of Manchester (GB)
- Corresponding author
- Choudhury, Robin P.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 54
- Issue
- 19
- Pages
- 1787-1794
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2104463342
- Cited by
- 246
- References
- 53
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 11 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 8 · 2017: 8 · 2016: 8 · 2015: 13 · 2014: 16 · 2013: 29 · 2012: 40
- FWCI
- 43.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Merck KGaA
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0508-10247)
- University of Oxford
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- nicotinic acid, atherosclerosis, carotid intima-media thickness, vascular function, statin therapy, low HDL cholesterol, type 2 diabetes, coronary artery disease, endothelial function, lipid-lowering therapy
- MeSH terms
- Aged, Hypolipidemic Agents, Carotid Artery Diseases, Delayed-Action Preparations, Double-Blind Method, Drug Administration Schedule, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Magnetic Resonance Imaging, Male, Middle Aged, Niacin, Time Factors, Triglycerides, Confounding Factors, Epidemiologic, Treatment Outcome, Tunica Intima, Tunica Media
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
